BMY - NYSE
Bristol-Myers Squibb Company
$54.72
-0.42%Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
At a Glance
Live SnapshotBristol-Myers Squibb Company Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Bristol-Myers Squibb Company Cash Flow Statement
BMY • NYSE
| Bristol-Myers Squibb Company Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
7.1B | -8.9B | 8B | 6.3B | 7B | -9B | 3.5B | 4.9B | 975M | 4.5B | 1.6B | 2B | 2.6B | 2.5B | 5.3B | 4.5B | 11.9B | 6.2B | 2.2B | 1.6B | |
4B | 9.6B | 9.8B | 10.3B | 10.7B | 10.4B | 1.7B | 637M | 789M | 382M | 376M | 467M | 763M | 681M | 628M | 607M | 707M | 816M | 892M | 927M | |
-965M | -2.1B | -3.3B | -2.7B | -1.4B | 983M | -924M | 45M | 453M | -204M | -347M | -542M | -491M | -1.2B | 415M | 422M | 163M | 1.4B | -416M | -236M | |
553M | 507M | 518M | 457M | 583M | 779M | 441M | 221M | 199M | 205M | 235M | 213M | 191M | 154M | 161M | 193M | 183M | 181M | 0.0 | 0.0 | |
4B | 15.3B | 744M | 955M | 578M | 9.9B | 317M | 999M | 714M | -680M | 945M | 739M | 308M | 5.5B | -1.7B | -1.2B | -8.9B | -5.1B | 670M | 447M | |
-455M | 810M | -1.9B | -2.2B | -1.3B | 983M | 3.2B | 217M | 2.1B | -1.2B | -735M | 242M | 194M | -631M | 46M | -29M | 42M | 117M | -158M | -640M | |
14.2B | 15.2B | 13.9B | 13.1B | 16.2B | 14.1B | 8.2B | 7.1B | 5.3B | 3.1B | 2.1B | 3.1B | 3.5B | 6.9B | 4.8B | 4.5B | 4.1B | 3.7B | 3.2B | 2.1B | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-1.3B | -1.2B | -1.2B | -1.1B | -973M | -753M | -836M | -951M | -1.1B | -1.2B | -820M | -526M | -537M | -548M | -367M | -424M | -730M | -941M | -843M | -793M | |
-2.9B | -20.7B | -260M | -3B | -862M | -12.3B | -9.1B | -1.1B | (10M) | (975M) | -403M | (3.4B) | (9M) | -7.5B | -211M | -762M | -2.2B | -191M | -159M | (507M) | |
-2B | -769M | -1.8B | -3.6B | -5.5B | -4.2B | -4B | -2.3B | -5.4B | -3.1B | -3.1B | -5.7B | -1.9B | -3.6B | -6.8B | -5.8B | -3.5B | -422M | -19.9B | (0.0) | |
2.1B | 1.4B | 948M | 6.6B | 6.8B | 6.4B | 4B | 2.4B | 6.4B | 4.8B | 2.8B | 4.1B | 1.8B | 4.9B | 6B | 3.2B | 2.1B | 1.6B | 20.6B | 762M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4M | 5.1B | 44M | -270M | |
-4.1B | -21.4B | -2.3B | -1.1B | -538M | -10.9B | -9.9B | -2B | -66M | (1.5B) | -1.6B | (1.2B) | -572M | -6.7B | -1.4B | -3.8B | -4.4B | (5.1B) | -202M | (206M) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-128M | 0.0 | -5.2B | -8B | -6.3B | -1.5B | -7.3B | -320M | -2.5B | -231M | 0.0 | 288M | 131M | -1.9B | -620M | -324M | 827M | 5M | 333M | 170M | |
-5.2B | 10.1B | 456M | -5.3B | -6.2B | 3.9B | 17.7B | -548M | 991M | 110M | -1.1B | -432M | 1.1B | -109M | -79M | -963M | 1.4B | -337M | -1.3B | -1.2B | |
-5B | -4.9B | -4.7B | -4.6B | -4.4B | -4.1B | -2.7B | -2.6B | -2.6B | -2.5B | -2.5B | -2.4B | -2.3B | -2.3B | -2.3B | -2.2B | -2.5B | -2.5B | -2.2B | -2.2B | |
(0.0) | (0.0) | -5.2B | -8B | -6.3B | -1.5B | -7.3B | -320M | -2.5B | -231M | (0.0) | (0.0) | -433M | -2.4B | -1.2B | -576M | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -106M | 27M | 984M | 641M | 542M | -53M | -54M | -22M | 15M | -9M | 105M | 20M | 2M | 296M | 146M | 194M | 211M | 0.0 | -158M | |
-10.3B | 5.1B | -9.4B | -17B | -16.2B | -1.2B | 7.6B | -3.5B | -4.1B | -2.7B | -3.6B | -2.4B | -1.1B | -4.3B | -2.7B | -3.3B | -17M | -2.6B | -3.2B | -3.4B | |
CASH FLOW SUMMARY | ||||||||||||||||||||
187M | -137M | 45M | -33M | -102M | 111M | -9M | -41M | 52M | -33M | -95M | 58M | 25M | -1M | -3M | 14M | 39M | -29M | 45M | 30M | |
-137M | -1.2B | 2.2B | -5B | -657M | 2.2B | 5.9B | 1.5B | 1.2B | 1.9B | -3.2B | 2B | 1.9B | -4.1B | 743M | -2.7B | -293M | 6.2B | -217M | -1B | |
10.3B | 11.5B | 9.3B | 14.3B | 15B | 12.8B | 6.9B | 5.4B | 4.2B | 2.4B | 5.6B | 3.6B | 1.7B | 5.8B | 5B | 7.7B | 8B | 1.8B | 2B | 3.1B | |
10.2B | 10.3B | 11.5B | 9.3B | 14.3B | 15B | 12.8B | 6.9B | 5.4B | 4.2B | 2.4B | 5.6B | 3.6B | 1.7B | 5.8B | 5B | 7.7B | 8B | 1.8B | 2B | |
12.8B | 13.9B | 12.7B | 11.9B | 15.2B | 13.3B | 7.4B | 6.1B | 4.2B | 1.8B | 1.3B | 2.6B | 3B | 6.4B | 4.5B | 4.1B | 3.3B | 2.8B | 2.3B | 1.3B |
SEC Filings
BMY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 08, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 25, 2026 | May 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 18, 2025 | November 17, 2025 | 2025 |
Related Guides
Continue your BMY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.